Buy or sell HeartFlow stock pre IPO via an EquityZen fund
EquityZen is a marketplace for shares of proven pre IPO tech companies
HeartFlow Stock
Medical Technology Company
About HeartFlow Stock
HeartFlow is a medical technology company that provides new methods of diagnosis and treatment of cardiovascular disease. It offers HeartFlow Analysis, a non-invasive solution available in the United States, Europe, and Japan that helps a physician evaluate whether a patient has significant coronary artery disease based on anatomy and physiology.
Investors
Baillie Gifford
Spotify, Indigo, Ginkgo Bioworks, Joby Aviation, AUTO1 Group, Carbon, Tempus, HeartFlow, Graphcore, Thumbtack
Capricorn Investment Group
LifeForce Capital
HeartFlow, One Medical, Clover Health, Vineti, Verge Genomics
Martis Capital
Funding History
| July 2009 | $2.0M |
|---|---|
| August 2010 | $6.9M |
| August 2010 | $10.1M |
| December 2011 | $105M |
| January 2015 | $111M |
| November 2017 | $340M |
Management
Chief Executive Officer
Dana Mead
Chief Technology Officer
Charles Anthony Taylor
Press
BioWorld - Jan, 31 2020
businesswire - Sep, 12 2019
bioportfolio - May, 23 2019
computerworlduk - Feb, 21 2019
massdevice - Feb, 8 2019
Other Companies
EquityZen does not have an affiliation with, formal relationship with, or endorsement from HeartFlow or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
